1 / 67

Future Pharmaceutical Trends - Patent & Pipeline –

Future Pharmaceutical Trends - Patent & Pipeline – . Chris Peterson, PharmD Aimee Tharaldson, PharmD. Objectives. Patent Expiration Overview: 2011-2013 Traditional Pipeline Highlights Specialty Pipeline Overview. Objectives. Patent Expiration Overview: 2011-2013

briana
Download Presentation

Future Pharmaceutical Trends - Patent & Pipeline –

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Future Pharmaceutical Trends- Patent & Pipeline – Chris Peterson, PharmD Aimee Tharaldson, PharmD

  2. Objectives • Patent Expiration Overview: 2011-2013 • Traditional Pipeline Highlights • Specialty Pipeline Overview

  3. Objectives • Patent Expiration Overview: 2011-2013 • Traditional Pipeline Highlights • Specialty Pipeline Overview

  4. Patent Expiration Landscape $ Billion 4

  5. Patent Expiration LandscapeNext 5 Years $ Billion 5

  6. Patent Expiration LandscapeNext 5 Years $ Billion Nexium Celebrex Actonel Abilify Gleevec Namenda Cymbalta OxyContin Niaspan 6

  7. Patent Expirations: 2011 * Settlement Agreement

  8. Patent Expirations: 2011 * Settlement Agreement

  9. Patent Expirations: 2012 * Settlement Agreements

  10. Patent Expirations: 2012 * Settlement Agreements

  11. Patent Expirations: 2012 * Settlement Agreements

  12. Patent Expirations: 2012 * Settlement Agreements

  13. Patent Expirations: 2012 * Settlement Agreements

  14. Patent Expirations: 2013 * Settlement Agreement

  15. Patent Expirations: 2013 * Settlement Agreement 15

  16. Objectives • Patent Expiration Overview: 2011-2013 • Traditional Pipeline Highlights • Specialty Pipeline Overview 16

  17. Cardiovascular Pipeline Xarelto(rivaroxaban – Bayer/J&J) Indication: Stroke/systemic embolism in a-fib. Route: Oral (once daily) Comments: Approved July 1, 2011. Also under FDA Review for a-fib indication (Nov. 5, 2011). Eliquis(apixaban – BMS/Pfizer) Indication: Stroke/systemic embolism in a-fib. Route: Oral (twice daily) Comments: Submission of NDA by the end of 2011 with FDA approval in 2012. 17

  18. FDA Action Dates: Cardiovascular 18

  19. Diabetes Pipeline Dapagliflozin(AstraZeneca/BMS) Indication: Type 2 diabetes Route: Oral (two times daily) Comments: FDA Ad Board held on July 19. FDA action date is October 28, 2011. Bydureon(exenatide LAR – Amylin/Lilly) Indication: Type 2 diabetes Route: subcutaneous injection (once weekly) Comments: “Complete response” received in March 2011. FDA action date is January 28, 2012. 19

  20. Diabetes Pipeline Insulin Degludec(Novo-Nordisk) Indication: Diabetes Route: Subcutaneous injection (three times weekly) Comments: Long-acting basil insulin. Submission planned by the end of 2011. 20

  21. FDA Action Dates: Diabetes 21

  22. Respiratory Pipeline Eklira (aclidinium – Forest) Indication: COPD Route: Inhalation (twice daily) Comments: FDA Action date is Apr 30, 2012. Glycopyrronium (NVA237 – Novartis) Indication: COPD Route: Inhalation (once daily) Comments: NDA submission planned by the end of 2011. 22

  23. FDA Action Dates: Respiratory 23

  24. CNS Pipeline Opana ER (oxymorphonee.r. – Endo) Indication: Chronic pain Route: Oral (Twice daily) Comments: “Tamper resistant” formulation. FDA Action date is Dec 13, 2011. Remoxy (oxycodonee.r. – Pfizer) Indication: Chronic pain Route: Oral (Twice daily) Comments: “Tamper resistant” formulation. Complete response issued in in June. 24

  25. CNS Pipeline Levomilnacipran (Forest) Indication: Depression Route: Oral (once daily) Comments: Isomer of milnacipran (Savella). NDA by expected “early 2012”. 25

  26. CNS Pipeline Levadex(dihydroergotamine - MAP) Indication: Acute migraine Route: Inhalation Comments: Asthma-sized inhaler device. FDA Action date is Mar 26, 2012. 26

  27. FDA Action Dates: CNS 27

  28. FDA Action Dates: Other 28

  29. Objectives • Patent Expiration Overview: 2011-2013 • Traditional Pipeline Highlights • Specialty Pipeline Overview 29

  30. FDA New Drug Approvals Traditional Specialty Source: U.S. Food and Drug Administration

  31. Specialty Trend Continues to Dwarf Traditional PMPY Annual Trend Source: Express Scripts’ Drug Trend Report data and Forecasting Specialty Traditional

  32. Top Specialty Therapy Classes $37 $30 $22 PMPY 2010 PMPY Source: Express Scripts’ Drug Trend Report data

  33. Therapy Class Review • Inflammatory Conditions • Multiple Sclerosis • Cancer • Hepatitis C • Cystic Fibrosis • Other Drugs to Watch

  34. Inflammatory ConditionsPipeline Trends • Oral biologics will compete with injectables • More therapies for gout? • “Biobetters” on the horizon

  35. Inflammatory ConditionsPipeline RA = Rheumatoid Arthritis; PA = Psoriatic Arthritis *Already on the market for another indication or different route

  36. Oral Biologics Apremilast (Celgene) Indication: Psoriasis, Psoriatic Arthritis Route: Oral (twice daily) Comments:Inhibits inflammatory cytokines; Approval in 2012 for psoriasis Tofacitinib (Pfizer) Indication: Rheumatoid Arthritis, Psoriasis Route: Oral (twice daily) Comments: Inhibits JAK; Approval in 2012 for RA RA = Rheumatoid Arthritis JAK = Janus Kinase

  37. Gout Ilaris (canakinumab - Novartis) Indication: Treatment and prevention of acute gout Route: SQ Injection Comments: Negative Ad Board, CRL in August Arcalyst (rilonacept - Regeneron) Indication: Treatment and prevention of acute gout Route: SQ Injection Comments: Approval in 2012? - Both already on market for CAPS - CRL = Complete Response Letter; CAPS = Cryopyrin-Associated Periodic Syndromes

  38. Multiple Sclerosis Pipeline Trends • More oral disease-modifying drugs • May see combination use of MS drugs • Expanded MS use for currently marketed drugs

  39. Multiple Sclerosis Pipeline *Already on the market for another indication

  40. Oral Disease-Modifying Drugs for MS DimethylFumarate(BG-12 – Biogen Idec) Indication: Relapsing Remitting Multiple Sclerosis Route: Oral (two times daily) Comments: Approval in 2012; G.I./flushing issues Laquinimod(Teva / Active Biotech) Indication: Relapsing Remitting Multiple Sclerosis Route: Oral (once daily) Comments: Approval in 2012; May liver enzymes

  41. Currently Marketed Drugs Expand into MS Lemtrada (alemtuzumab - Genzyme) Indication: Relapsing Remitting Multiple Sclerosis Route: IV Infusion (5 then 3 days per year) Comments: Approved for CLL; ITP and infection risk Zenapax (daclizumab – Biogen Idec/Abbott) Indication: Relapsing Remitting Multiple Sclerosis Route: SQ Injection (once monthly) Comments: Approved for transplant; Infection and liver toxicity risk CLL = Chronic Lymphocytic Leukemia; ITP = Immune Thrombocytopenic Purpura

  42. Cancer Pipeline Trends • Cancer treated as a chronic condition • Oral drugs • Targeted therapies • Niche or orphan cancer types • Pharmacogenomics plays a role

  43. 2011 Cancer Drug Approvals HL = Hodgkin’s Lymphoma; ALCL = Anaplastic Large Cell Lymphoma; NSCLC = Non-Small Cell Lung Cancer

  44. Pharmacogenomics Zalboraf(vemurafenib – Genentech) Indication: Malignant Melanoma Route: Oral (twice daily) Comments: For patients with BRAF mutation; Approved Aug. 17th Xalkori(crizotinib - Pfizer) Indication: Non-Small Cell Lung Cancer Route: Oral (twice daily) Comments: For patients with ALK mutation; Approved Aug. 26th

  45. Cancer Pipeline- 2011 – Erwinaze (crisantaspase – EUSA) Indication: Acute Lymphoblastic Leukemia Route: IM (every other day) Comments: Cell growth inhibitor; Approval in 2011 Ruxolitinib(Incyte) Indication: Myelofibrosis Route: Oral (twice daily) Comments: JAK inhibitor; FDA action: Dec 3rd JAK = Janus Kinase

  46. Cancer Pipeline- 2012 - NHL = Non-Hodgkin’s Lymphoma; CML = Chronic Myeloid Leukemia; NSCLC = Non-Small Cell Lung Cancer

  47. Cancer Pipeline- 2012 - NHL = Non-Hodgkin’s Lymphoma; CML = Chronic Myeloid Leukemia; NSCLC = Non-Small Cell Lung Cancer

  48. Cancer Pipeline- 2012 - NHL = Non-Hodgkin’s Lymphoma; CML = Chronic Myeloid Leukemia; NSCLC = Non-Small Cell Lung Cancer

  49. Oral Drugs for Cancer Axitinib (Pfizer) Indication: Renal Cell Carcinoma Route: Oral (twice daily) Comments: Angiogenesis inhibitor; FDA approval expected in April 2012 Ridaforolimus (Merck) Indication: Soft-Tissue and Bone Sarcomas Route: Oral (once daily x 5 days each week) Comments: mTOR inhibitor; Approval in April 2012

  50. Hepatitis C Pipeline Trends • Oral protease inhibitors hit the market • Watch for more direct acting antivirals • Novel interferons in 2-3 years

More Related